echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Sichuan Guowei Pharmaceutical Co., Ltd.'s first imitation of "dutasteride soft capsule" was approved

    Sichuan Guowei Pharmaceutical Co., Ltd.'s first imitation of "dutasteride soft capsule" was approved

    • Last Update: 2020-01-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In vernacular On January 16, Sichuan Guowei Pharmaceutical Co., Ltd declared dutasteride soft capsules according to the new 4 categories, which was approved by the State Food and Drug Administration for listing, was deemed to have passed the consistency evaluation Dutasteride is a 5 α - reductase inhibitor developed by GSK It was first approved by FDA on November 20, 2001, and was approved on March 23, 2011 in China for the treatment of moderate and severe symptoms of benign prostatic hyperplasia (BPH) Its trade name is anfuda In 2018, anfuda's global sales were £ 572 million.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.